Halozyme (HALO) Q2 2026 earnings review
Record Royalties Drive Massive Guidance Raise
Halozyme delivered a blockbuster quarter, fueled by 50% year-over-year royalty revenue growth to $308 million. The core ENHANZE franchise, driven by heavy hitters like DARZALEX SC and VYVGART Hytrulo, is generating exceptional operating leverage. Management significantly raised full-year 2026 guidance across all metrics, bumping the midpoint of their EPS target up by over 10%. With five new collaboration agreements signed YTD—exceeding their full-year goal of three—and an aggressive $333 million deployed into share buybacks during the quarter, the fundamental growth engine is firing on all cylinders.
🐂 Bull Case
Royalty revenue exploded 50% YoY, generating a 68% Adjusted EBITDA margin. The uptake of newly launched partner products provides a highly visible, durable revenue stream.
The company repurchased 4.8 million shares for $333 million in Q2 alone, heavily supporting the 108%+ YoY EPS growth guided for FY26.
🐻 Bear Case
Ongoing patent litigation against Merck is draining real cash. Excluded intellectual property litigation costs nearly tripled YoY to $6.9M in Q2.
While royalties shine, the product sales segment saw gross margins compress due to higher costs associated with bulk rHuPH20 sales, indicating some negative mix shifts in the physical supply side of the business.
⚖️ Verdict: 🟢🟢
Strongly Bullish. The sheer magnitude of the guidance raise, combined with 50% royalty growth and massive capital returns, overrides the minor friction of rising litigation and integration costs.
Key Themes
Core Royalty Acceleration
The ENHANZE platform continues to compound at a remarkable rate. Royalty revenue of $307.7 million was up 50% YoY, accelerating from the 43% YoY growth seen in Q1. This is underpinned by the entrenched success of VYVGART Hytrulo and DARZALEX SC. The flow-through to the bottom line is immense, driving Adjusted EBITDA up 46% YoY to $328.8 million.
Deal Execution Exceeds Targets
Management had set a goal of signing three new collaboration agreements for the entirety of 2026. By July, they had already signed five. These include major deals with Incyte, Vertex, Oruka, GSK (specifically targeting ADCs), and a breakthrough undisclosed partnership for a nucleic acid therapeutic. This rapid deal flow heavily de-risks the long-term pipeline post-2029.
Aggressive Share Count Reduction
Halozyme is weaponizing its free cash flow. After completing its February 2024 share repurchase program, the company immediately tapped into its new $1.0 billion authorization, repurchasing 4.8 million shares for $332.8 million in Q2 (average price $69.30). This massive buyback strategy provides a permanent tailwind to EPS.
Product Sales Margin Dilution
While total revenues are surging, the physical supply side of the business is experiencing friction. Product sales (net) grew 59% YoY to $129.6 million, but Cost of Sales jumped 71% YoY to $79.2 million. This implies a drop in the gross margin on physical products to approximately 39% (down from roughly 43% a year ago). Management attributed this to an increase in bulk rHuPH20 sales, contradicting the narrative of purely frictionless margin expansion.
Escalating Excluded Litigation Costs
The ongoing district court patent infringement case against Merck is becoming increasingly expensive. The company excluded $6.9 million of IP litigation costs from its Q2 Adjusted EBITDA metric, a sharp increase from the $2.6 million excluded in the prior year. While management adjusts this out of their preferred KPIs, it remains a real, growing cash burden and highlights the underlying legal risk to their core IP.
M&A Integration Costs Realized
The strategic acquisitions of Elektrofi and Surf Bio in late 2025 are structurally raising Halozyme's expense floor. Amortization of intangibles spiked to $29.5 million (up from $17.8 million YoY), while R&D and SG&A expenses also saw significant double-digit percentage increases directly attributed to the integrations and associated consulting fees.
Other KPIs
Accelerating. Up 46% YoY from $225.5 million in Q2 2025. Demonstrates the massive operating leverage embedded in the royalty business model, even with the structural increase in operating expenses following the 2025 M&A activity.
Accelerating. Increased from $145.4 million at the end of 2025. This cash build is particularly impressive given that the company deployed nearly $333 million into share repurchases during the quarter, highlighting exceptional free cash flow generation.
Accelerating. Representing a 48% YoY jump from $1.54 in Q2 2025. This beat is a dual-engine result: soaring net income combined with a heavily reduced share count.
Guidance
Accelerating. Management raised the range from $1.710-$1.810B. The new midpoint ($1.872B) implies a 34% YoY growth rate over FY25, heavily driven by the royalty engine and product sales.
Accelerating. Raised from $1.130-$1.170B. Represents exceptional 41% to 43% YoY growth. This indicates that the Q2 royalty beat was not just a timing difference, but a structural shift in partner demand.
Accelerating. Raised from $1.125-$1.205B. This represents 86% to 95% YoY growth over FY25, signaling that operating margins will remain historically high despite the $60M slated for Hypercon/Surf Bio investments.
Accelerating. Raised heavily from the prior $7.75-$8.25 target. The new guidance implies 108% to 117% YoY growth. Crucially, management noted this figure does *not* consider the impact of potential future share repurchases, suggesting further upside is likely.
Key Questions
Product Mix Dilution
Product sales margins compressed sequentially and year-over-year. As bulk rHuPH20 sales increase, how much of a drag will this place on the total corporate gross margin profile through the remainder of the year?
Litigation Cost Trajectory
Excluded intellectual property litigation costs reached $6.9 million this quarter. With key decisions in the Merck case not expected until 2026, should we view this level of cash burn as the new quarterly run-rate for the next 12-18 months?
Hypercon Pipeline Advancement
With the 2026 collaboration goal already exceeded in July, are we seeing any acceleration in the timeline for the first Hypercon Phase 1 clinical starts, which were previously pushed to H1 2027?